Puberty blockers for people aged under 18 with gender dysphoria will be indefinitely banned by the UK Government.

Meitheal Pharmaceuticals has gained exclusive US commercial rights for XENLETA for treating CABP in the adult population.

In a new webinar, industry experts explain how innovative technology is reshaping healthcare delivery, enabling proactive interventions that improve patient outcomes, relieve NHS pressures, and pave ...

The push to replace Albert Bourla as Pfizer’s CEO drew attention from the pharma industry but was soon derailed by several events.

Sanofi has announced that its two combination vaccine candidates have received fast track status from the US FDA.

When a room of physicians at ASH 2024 was asked whether they had prescribed a gene therapy in a commercial context, only a handful said yes.

If accepted, Vifor Pharma's £23m offer will "claw back" money for the NHS and close the CMA's first-ever disparagement case.

Er-Kim has extended its exclusive agreement with Ascendis Pharma for endocrinology treatments across multiple countries in Eurasia.